Encouraging Q2 21; but keep a close eye on COVID-19 situation
21/07/21 -"Novartis reported promising Q2 21 results, driven by a combination of improving pandemic situation and ‘softer comps’, i.e. reversal of forward buying in Q2 20. Most importantly, some momentum ..."
Pages
68
Language
English
Published on
21/07/21
You may also be interested by these reports :
17/09/25
The massive collapse in Novo Nordisk’s share price over the last 15 months, due to competitive concerns, pricing pressure and a few other factors, ...
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum